94 related articles for article (PubMed ID: 1674161)
1. Savoxepine: invalidation of an "atypical" neuroleptic response pattern predicted by animal models in an open clinical trial with schizophrenic patients.
Wetzel H; Wiedemann K; Holsboer F; Benkert O
Psychopharmacology (Berl); 1991; 103(2):280-3. PubMed ID: 1674161
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of a new antipsychotic compound (savoxepine): results of a pilot-study.
Möller HJ; Kissling W; Dietzfelbinger T; Stoll KD; Wendt G
Pharmacopsychiatry; 1989 Jan; 22(1):38-41. PubMed ID: 2565583
[TBL] [Abstract][Full Text] [Related]
3. Neuroleptic profile of cipazoxapine (Savoxepine), a new tetracyclic dopamine antagonist: clinical validation of the hippocampus versus striatum ratio model of dopamine receptors in animals. A preliminary report.
Butler B; Bech P
Pharmacopsychiatry; 1987 May; 20(3):122-6. PubMed ID: 2885867
[TBL] [Abstract][Full Text] [Related]
4. Savoxepine versus haloperidol. Reasons for a failed controlled clinical trial in patients with an acute episode of schizophrenia.
Volz HP; Möller HJ; Gerebtzoff A; Bischoff S
Eur Arch Psychiatry Clin Neurosci; 2002 Apr; 252(2):76-80. PubMed ID: 12111340
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of pharmaco-electroencephalography in early human-pharmacological evaluations of psychoactive drugs. First example: savoxepine.
Herrmann WM; Schärer E; Delini-Stula A
Pharmacopsychiatry; 1991 Nov; 24(6):196-205. PubMed ID: 1687485
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses].
Chabannes JP; Pelissolo A; Farah S; Gerard D
Encephale; 1998; 24(4):386-92. PubMed ID: 9809244
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
[TBL] [Abstract][Full Text] [Related]
8. Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters.
Wetzel H; Szegedi A; Hain C; Wiesner J; Schlegel S; Benkert O
Psychopharmacology (Berl); 1995 May; 119(2):231-8. PubMed ID: 7659771
[TBL] [Abstract][Full Text] [Related]
9. Savoxepine fails to selectively influence glucose metabolism in the rat limbic system.
Cascella NG; Tarazi FI; Shirakawa O; Tamminga CA
Psychopharmacology (Berl); 1994 Mar; 114(2):275-80. PubMed ID: 7838920
[TBL] [Abstract][Full Text] [Related]
10. Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine.
Bodkin JA; Cohen BM; Salomon MS; Cannon SE; Zornberg GL; Cole JO
J Nerv Ment Dis; 1996 May; 184(5):295-301. PubMed ID: 8627275
[TBL] [Abstract][Full Text] [Related]
11. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Tada M; Shirakawa K; Matsuoka N; Mutoh S
Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia.
Cohen JD; Van Putten T; Marder S; Berger PA; Stahl SM
J Clin Psychopharmacol; 1987 Oct; 7(5):324-9. PubMed ID: 2890671
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the sigma receptor ligand EMD 57445 (panamesine) in patients with schizophrenia: an open clinical trial.
Huber MT; Gotthardt U; Schreiber W; Krieg JC
Pharmacopsychiatry; 1999 Mar; 32(2):68-72. PubMed ID: 10333165
[TBL] [Abstract][Full Text] [Related]
15. Quetiapine : A Review of its Use in Schizophrenia.
Gunasekara NS; Spencer CM
CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
[TBL] [Abstract][Full Text] [Related]
16. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group.
Chouinard G; Kopala L; Labelle A; Beauclair L; Johnson SV; Singh KI
Can J Psychiatry; 1998 Dec; 43(10):1018-25. PubMed ID: 9868567
[TBL] [Abstract][Full Text] [Related]
17. The predictive value of psychopathological subclassifications for the neuroleptic treatment outcome in schizophrenia.
Jarema M; Kacperczyk J; Kruszynski S
Psychopathology; 1991; 24(3):141-6. PubMed ID: 1684443
[TBL] [Abstract][Full Text] [Related]
18. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
[TBL] [Abstract][Full Text] [Related]
19. Serum neuroleptic levels and extrapyramidal side effects in patients treated with amoxapine.
Gaffney GR; Tune LE
J Clin Psychiatry; 1985 Oct; 46(10):428-9. PubMed ID: 2864332
[TBL] [Abstract][Full Text] [Related]
20. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
